Plus   Neg

TB Alliance, Mylan In Deal To Commercialize Pretomanid For TB Treatment

Mylan N.V. (MYL), and TB Alliance, a not-for-profit drug maker struck a deal to make the experimental drug pretomanid available for use in two investigational drug regimens to treat tuberculosis.

TB Alliance is currently developing pretomanid in three late-stage clinical trials, which are ongoing. The Nix-TB and ZeNix trials are evaluating the BPaL regimen to treat XDR-TB and the related highly resistant forms of TB. The SimpliciTB trial is evaluating the BPaMZ regimen for treating DS-TB in four months, and MDR-TB in six months.

In relation to BpaL regimen TB Alliance has now granted a license to Mylan to make and sell pretomanid, if approved, for XDR-TB and treatment-intolerant or non-responsive MDR-TB.

In the BPaMZ regimen, TB Alliance has licensed pretomanid to for DS- and MDR-TB.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Alibaba is upgrading its intellectual property system using blockchain technology, according to local news outlet Sohu. Alibaba Platform Management expects this to benefit mainly small and medium-sized enterprises, brands and entrepreneurs. The technology will be fully implemented in September, and thereafter, the company intends to expand it to the field of digital copyright protection. Electronics retailer Best Buy Co., Inc. (BBY) reported Thursday a 27 percent increase in profit for the first quarter from last year, which was impacted by restructuring charges, and higher revenues. Both adjusted earnings per share and revenues for the quarter topped analysts' estimates. The company also provides guidance for the second quarter and reiterated its outlook for the full-year 2020. While reporting financial results for the second quarter on Thursday, Hormel Foods Corp. (HRL) lowered its earnings and net sales guidance for the full-year 2019. For fiscal 2019, the company now projects earnings in a range of $1.71 to $1.85 per share, and net sales between $9.70 billion and $10.20...
Follow RTT